Anthony Griffiths, PhD
Associate Professor
Boston University School of Medicine
Dept of Microbiology

PhD, University of Cambridge




The family Filoviridae includes Ebola virus and Marburg virus, which are associated with sporadic outbreaks and high case fatality rates. A maximum containment laboratory (Biosafety Level-4) is required to study the infectious forms of these viruses. Dr. Griffiths’ laboratory is interested in multiple aspects of filovirus biology with a view to exploiting this knowledge to further the development of vaccines and therapeutics.

Faculty
Boston University
National Emerging Infectious Disease Lab


Graduate Faculty (Primary Mentor of Grad Students)
Boston University School of Medicine, Graduate Medical Sciences




Exploratory Single-Dose Intramuscular Immunogenicity, Protection from SARS-CoV-2 and Evaluation of VAERD Study in Golden Syrian Hamsters
10/05/2020 - 10/04/2025 (Subcontract PI)
Merck, Sharp & Dohme Corp HHS ASPR BARDA
HHSO10020160031C

Discovery and development of antibody therapeutics for SARS-CoV-2 and other high-risk emerging viruses
10/30/2020 - 10/29/2023 (Subcontract PI)
President & Fellows of Harvard College on behalf of Harvard Medical School AbbVie


Pilot Study To Assess Protection against Filovirus challenge by an infused monoclonal antibody
10/31/2019 - 09/23/2023 (Subcontract PI)
Leidos NIH NCI
75N91019D00024

Restricted: Pilot Study To Assess Protection against Filovirus challenge by an infused monoclonal antibody
10/31/2019 - 09/23/2023 (Subcontract PI)
Leidos NIH NCI
75N91019D00024

Accelerated development of a SARS-CoV-2 vaccine based on the live VSVG chimeric virus platform
02/26/2021 - 06/30/2022 (Subcontract PI)
International AIDS Vaccine Initative Inc. DOD DTRA


Rationally Designed Pan-Ebolavirus Vaccine
12/01/2019 - 05/31/2022 (Subcontract PI)
Integrated BioTherapeutics, Inc. NIH NIAID
5R01AI132204-04

Model development/ refinement study Ebola virus Makona intranasal challenge
04/16/2021 - 04/16/2022 (PI)
Janssen Vaccines & Prevention B.V.


Efficacy of Wyss-vaccine platforms in hamster model of SARS-CoV-2 infection
12/01/2020 - 12/31/2021 (PI)
Hansjorg Wyss Institute for Biologically Inspired Engineering at Harvard


Immunogenicity and Efficacy Testing of Medical Countermeasures (Vaccines and Other Biologics) Against BSL-4 Pathogens in NHPs
06/23/2020 - 12/31/2021 (Subcontract PI)
Battelle Memorial Institute NIH NIAID


Moderna SARS-CoV-2 Hamster challenge study (150)
03/20/2021 - 09/20/2021 (PI)
Moderna Therapeutics


Showing 10 of 31 results. Show All Results


Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Das Adhikari U, Eng G, Farcasanu M, Avena LE, Choudhary MC, Triant VA, Flagg M, Schiff AE, Gomez I, Froehle LM, Diefenbach TJ, Ronsard L, Lingwood D, Lee GC, Rabi SA, Erstad D, Velmahos G, Li JZ, Hodin R, Stone JR, Honko AN, Griffiths A, Yilmaz O, Kwon DS. Fecal SARS-CoV-2 RNA is associated with decreased COVID-19 survival. Clin Infect Dis. 2021 Jul 10.View Related Profiles. PMID: 34245255
     
  2. Niemuth NA, Fallacara D, Triplett CA, Tamrakar SM, Rajbhandari A, Florence C, Ward L, Griffiths A, Carrion R, Goez-Gazi Y, Alfson KJ, Staples HM, Brasel T, Comer JE, Massey S, Smith J, Kocsis A, Lowry J, Johnston SC, Nalca A, Goff AJ, Shurtleff AC, Pitt ML, Trefry J, Fay MP. Natural history of disease in cynomolgus monkeys exposed to Ebola virus Kikwit strain demonstrates the reliability of this non-human primate model for Ebola virus disease. PLoS One. 2021; 16(7):e0252874. PMID: 34214118; PMCID: PMC8253449; DOI: 10.1371/journal.pone.0252874;
     
  3. Johnson RI, Boczkowska B, Alfson K, Weary T, Menzie H, Delgado J, Rodriguez G, Carrion R, Griffiths A. Identification and characterization of defective viral genomes in Ebola virus infected rhesus macaques. J Virol. 2021 Jun 23; JVI0071421. PMID: 34160256
     
  4. Clark SA, Clark LE, Pan J, Coscia A, McKay LGA, Shankar S, Johnson RI, Brusic V, Choudhary MC, Regan J, Li JZ, Griffiths A, Abraham J. SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms. Cell. 2021 05 13; 184(10):2605-2617.e18.View Related Profiles. PMID: 33831372; PMCID: PMC7962548; DOI: 10.1016/j.cell.2021.03.027;
     
  5. Peddinti BST, Downs SN, Yan J, Smith SD, Ghiladi RA, Mhetar V, Tocchetto R, Griffiths A, Scholle F, Spontak RJ. Rapid and Repetitive Inactivation of SARS-CoV-2 and Human Coronavirus on Self-Disinfecting Anionic Polymers. Adv Sci (Weinh). 2021 06; 8(11):e2003503. PMID: 34105286; PMCID: PMC7994973; DOI: 10.1002/advs.202003503;
     
  6. Alfson KJ, Goez-Gazi Y, Gazi M, Staples H, Mattix M, Ticer A, Klaffke B, Stanfield K, Escareno P, Keiser P, Griffiths A, Chou YL, Niemuth N, Meister GT, Cirimotich CM, Carrion R. Development of a Well-Characterized Rhesus Macaque Model of Ebola Virus Disease for Support of Product Development. Microorganisms. 2021 Feb 26; 9(3). PMID: 33652589; PMCID: PMC7996724; DOI: 10.3390/microorganisms9030489;
     
  7. Atyeo C, Slein MD, Fischinger S, Burke J, Schäfer A, Leist SR, Kuzmina NA, Mire C, Honko A, Johnson R, Storm N, Bernett M, Tong P, Zuo T, Lin J, Zuiani A, Linde C, Suscovich T, Wesemann DR, Griffiths A, Desjarlais JR, Juelg BD, Goudsmit J, Bukreyev A, Baric R, Alter G. Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022. JCI Insight. 2021 01 11; 6(1).View Related Profiles. PMID: 33427208; PMCID: PMC7821590; DOI: 10.1172/jci.insight.143129;
     
  8. Xiao T, Lu J, Zhang J, Johnson RI, McKay LGA, Storm N, Lavine CL, Peng H, Cai Y, Rits-Volloch S, Lu S, Quinlan BD, Farzan M, Seaman MS, Griffiths A, Chen B. A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent. Nat Struct Mol Biol. 2021 02; 28(2):202-209.View Related Profiles. PMID: 33432247; PMCID: PMC7895301; DOI: 10.1038/s41594-020-00549-3;
     
  9. Zabaleta N, Dai W, Bhatt U, Chichester JA, Estelien R, Sanmiguel J, Michalson KT, Diop C, Maciorowski D, Qi W, Hudspeth E, Cucalon A, Dyer CD, Pampena MB, Knox JJ, LaRocque RC, Charles RC, Li D, Kim M, Sheridan A, Storm N, Johnson RI, Feldman J, Hauser BM, Ryan A, Kobayashi DT, Chauhan R, McGlynn M, Ryan ET, Schmidt AG, Price B, Honko A, Griffiths A, Yaghmour S, Hodge R, Betts MR, Freeman MW, Wilson JM, Vandenberghe LH. Immunogenicity of an AAV-based, room-temperature stable, single dose COVID-19 vaccine in mice and non-human primates. bioRxiv. 2021 Jan 05.View Related Profiles. PMID: 33442684; PMCID: PMC7805441; DOI: 10.1101/2021.01.05.422952;
     
  10. Storm N, McKay LGA, Downs SN, Johnson RI, Birru D, de Samber M, Willaert W, Cennini G, Griffiths A. Rapid and complete inactivation of SARS-CoV-2 by ultraviolet-C irradiation. Sci Rep. 2020 12 30; 10(1):22421.View Related Profiles. PMID: 33380727; PMCID: PMC7773738; DOI: 10.1038/s41598-020-79600-8;
     
Showing 10 of 58 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 58 publications over 16 distinct years, with a maximum of 9 publications in 2021

YearPublications
19981
20032
20051
20063
20071
20091
20115
20123
20143
20156
20163
20174
20184
20195
20207
20219
Contact for Mentoring:

620 Albany Street
Boston MA 02118
Google Map


Griffiths's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department